Interestingly, during these efforts triple-acting AChE/BChE/MAO B inhibitors were discovered, which could benefit from the additional inhibition of BChE whose increased expression and activity has been documented in chronic AD (Arendt et al., 1992). The gene discussed is BCHE; the disease is Alzheimer disease.